Form 4: Fairmount Funds Reports Director Stock Option Grant
Statement of Changes in Beneficial Ownership
Fairmount Funds Management and associated directors were granted 34,843 stock options in Jade Biosciences, Inc.
Summary
- Fairmount Funds Management LLC, along with associated entities and directors Tomas Kiselak and Peter Harwin, reported the acquisition of 34,843 stock options in Jade Biosciences, Inc. (JBIO).
- The options were granted on June 9, 2026, with an exercise price of $15.22 per share.
- The options are set to expire on June 8, 2036.
- The grant is subject to vesting on the earlier of June 9, 2027, or the date of the next annual stockholders' meeting, contingent upon continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.
Positives
- Alignment of interests between major shareholders/directors and the company through equity-based compensation.
Negatives
- Dilutive effect of new stock option grants on existing shareholders.
Risks
- Vesting is contingent upon Tomas Kiselak's continued service to the issuer.
- Market price volatility may impact the future value of the granted options.
Future Outlook
The options vest in one year, signaling a commitment to the company's long-term governance and performance.
Management Comments
- Tomas Kiselak is obligated to turn over any net cash or stock received from the option for the benefit of the Fairmount Funds.
Industry Context
StockSavvy.ai notes that director-level equity grants are standard practice in the biotechnology sector to ensure board alignment with long-term shareholder value, particularly for firms backed by institutional venture capital.
Comparison to Industry Standards
- The grant size and vesting schedule are consistent with standard corporate governance practices for venture-backed biotech companies.
- The use of 'director by deputization' is a common legal structure for institutional investors holding board seats.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 34,843 stock options to director Tomas Kiselak. | 06/09/2026 | Standard alignment of director incentives. |
Related Party Transactions
- Fairmount Funds Management LLC acts as the investment manager for the funds involved and holds a significant ownership stake.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of options on June 9, 2027, or the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 06/09/2026 | Date of transaction and grant of stock options. |
| 06/11/2026 | Date of filing. |
| 06/09/2027 | Vesting date for the stock options. |
| 06/08/2036 | Expiration date of the stock options. |
Keywords
Jade Biosciences, JBIO, Fairmount Funds, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.